A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system found below the bladder and in front of the rectum] become abnormal and start to grow uncontrollably, forming tumors) who have failed taxane (docetaxel)-based chemotherapy.

本研究旨在评估醋酸阿比特龙（abiraterone acetate）在经以紫杉烷类（多西他赛）为基础的化疗治疗失败的前列腺癌受试者中的抗肿瘤活性与安全性。前列腺癌是指前列腺（男性生殖系统的腺体，位于膀胱下方、直肠前方）的细胞发生异常改变并开始不受控增殖，进而形成肿瘤的疾病。